Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Astellas, US Biotech Venture to Collaborate on Mitochondrial Disease Therapies
October 8, 2013
- Quintiles Aims to Expand Business in Japan with More Employees: CEO
October 8, 2013
- Ethical Drug Sales Up 0.7% in August: Crecon Report
October 8, 2013
- 3 Combination Drugs for Asthma, COPD Get Approval to Fuel Competition; NHI Price Listing Expected in November
October 7, 2013
- Novartis AG Pharma Division Head Supports Ministry Panel’s Diovan Investigation Interim Report, Refuses to Comment on Whether Ads Were Exaggerated
October 7, 2013
- Nippon Shinyaku, Pfizer Japan Sign Deal for Promotional Activities for Tramal
October 7, 2013
- Novartis Japan Execs Face 30% Pay Cut amid Diovan Scandal, Compliance Advisory Board to Be Set Up
October 4, 2013
- Mundipharma Initiates Clinical Study of PTCL Treatment Pralatrexate in Japan
October 4, 2013
- Takeda, Tri-I TDI Conclude Research Deal
October 4, 2013
- Number of MRs Down Slightly to 63,846 as of March 2013; Are We Entering an Age of Decline for MRs?
October 4, 2013
- Nichi-Iko, South Korean Biotech Firm Partner Up on Biosimilar Business
October 3, 2013
- Nihon Chouzai to Increase Its Generic Portfolio to 1,000 in 2 Years: President Mitsuhara
October 3, 2013
- Asahi Kasei Pharma, Vernalis Sign Joint Research Agreement for New Drug Discoveries for Autoimmune Diseases
October 3, 2013
- Kissei, JCR to Jointly Develop Nesp Biosimilar
October 2, 2013
- Another Administrative Action Taken Against MTPC on Medway Injection; 3rd in 4 Years
October 2, 2013
- US FDA Approves Brintellix for Treatment of MDD in Adults: Takeda, Lundbeck
October 2, 2013
- Asahi Kasei Pharma, Pfizer Japan Strike Copromotion Deal for Recomodulin
October 2, 2013
- Nichi-Iko to Take Over Astellas’s Shizuoka Plant Next April
October 1, 2013
- Takeda Files for Approval of Hib Vaccine in Japan
October 1, 2013
- Amgen Astellas BioPharma to Go on Stream Oct. 1; JV Chief Takahashi Eager to Make It a “Category Leader”
September 30, 2013
ページ
AAV (adeno-associated virus) gene therapies are moving beyond rare diseases into more prevalent conditions, with neovascular, or wet, age-related macular…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…